-- 根據週三提交給印度證券交易所的文件顯示，瑞迪博士實驗室（Dr. Reddy's Laboratories，NSE：DRREDDY，BOM：500124）已收到加拿大監管機構－加拿大衛生部藥品管理局（Pharmaceutical Drugs Directorate，Health Canada）的合規通知書（NOC），批准其製藥製藥用索瑪魯勝肽（Sglide Injection Injection），批准其製藥製藥用索瑪魯肽。 該合規通知書授權在加拿大銷售、推廣和分銷糖尿病控制藥物索瑪魯肽注射。此次上市許可涵蓋2毫克/支（1.34毫克/毫升）和4毫克/支（1.34毫克/毫升）兩種規格。 活性藥物成分完全由瑞迪博士實驗室自主生產，成品目前由其生產夥伴OneSource Specialty Pharma（NSE：ONESOURCE，BOM：544292）負責生產。 該公司股價在近期交易中下跌近1%。
Related Articles
Asia
Willfar Information Technology's Q1 2026 Profit Rises 6%
Willfar Information Technology (SHA:688100), a 59.55%-owned subsidiary of Wasion Holdings (HKG:3393), reported 148.3 million yuan in attributable profit for the first quarter of 2026, up 6.4% from 139.4 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.Revenue fell 4.2% year on year to 531.9 million yuan, figures showed.
$HKG:3393$SHA:688100
Asia
Zhongjin Gold's 2025 Profit Jumps 46%
Zhongjin Gold's (SHA:600489) attributable profit rose 46% to 4.93 billion yuan in 2025 from 3.39 billion yuan in 2024, according to a Wednesday filing with the Shanghai bourse.Earnings per share at the non-ferrous metals miner increased to 1.02 yuan from 0.70 yuan in the previous year.Operating revenue grew 21% year over year to 79.1 billion yuan from 65.6 billion yuan.
$SHA:600489
Asia
Jinduicheng Molybdenum's Q1 Profit Jumps 33%, Revenue Rises 27%
Jinduicheng Molybdenum's (SHA:601958) net profit attributable to shareholders in the first quarter jumped 33% year on year to 901.6 million yuan, or 0.279 yuan per share, according to a Wednesday disclosure on Shanghai filing.The attributable profit a year earlier was almost 678 million yuan, or 0.210 yuan per share.Operating revenue rose 27% to 4.16 billion yuan from 3.28 billion yuan in the previous year.The Chinese molybdenum miner's shares jumped less than 7% at the close.
$SHA:601958